{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:02:29Z","timestamp":1785769349721,"version":"3.56.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are well-known medications commonly prescribed for type 2 diabetes management and pharmacologic management of obesity. While GLP-1 RAs have many positive effects on glycemic control and cardiovascular health, the secondary effect of weight loss can present a challenge in maintaining optimal prosthesis fitting and functionality among individuals with prosthetic limbs. More specifically, weight loss can lead to decreased muscle mass and volume of the residual limb, resulting in loosening of the prosthesis. In turn, individuals often require more frequent prosthetic adjustments to ensure their safety and comfort while using the prosthetic device. Herein, we describe 3 cases of semaglutide use in patients with prosthetic limbs who subsequently presented with a variety of complications, including skin breakdown, disproportionate residual limb volume loss, decreased prosthetic use, and increased residual limb pain. Such \u201cOzempic limbs\u201d have not yet been reported in the literature. These observations suggest that further research in GLP-1 RA selection is required for persons with amputation, as well as increased patient education regarding the unique complications.<\/jats:p>","DOI":"10.1097\/phm.0000000000002989","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T20:01:21Z","timestamp":1775764881000},"page":"657-660","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["\u201cOzempic Limb\u201d"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-2713","authenticated-orcid":false,"given":"Janelle","family":"Bykowski","sequence":"first","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine and Dentistry, Western University, Windsor Campus, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrick","family":"Loewen","sequence":"additional","affiliation":[{"name":"Loewen Prosthetic Services Ltd, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock","family":"Loewen","sequence":"additional","affiliation":[{"name":"Loewen Prosthetic Services Ltd, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Seslija","sequence":"additional","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine and Dentistry, Western University, Windsor Campus, Ontario, Canada"},{"name":"Department of Physical Medicine and Rehabilitation, H\u00f4tel-Dieu Grace Healthcare, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"APR","key":"R1-20260710","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fendo.2019.00260","article-title":"From the incretin concept and the discovery of GLP-1 to today\u2019s diabetes therapy","volume":"10","author":"Holst","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R2-20260710","first-page":"1","article-title":"CADTH health technology review: current utilization patterns of glucagon-like peptide-1 receptor agonists","volume":"2","author":"Vaanabouathong","year":"2022","journal-title":"Can J Health Technol"},{"key":"R3-20260710","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/oby.23622","article-title":"Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: a retrospective cohort study","volume":"31","author":"White","year":"2023","journal-title":"Obesity"},{"key":"R4-20260710","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1038\/s41591-025-03913-2","article-title":"Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency","volume":"31","author":"Bhatnagar","year":"2025","journal-title":"Nat Med"},{"key":"R5-20260710","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"issue":"S4","key":"R6-20260710","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R7-20260710","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1682\/JRRD.2010.09.0189","article-title":"Residual limb volume change: systematic review of measurement and management","volume":"48","author":"Sanders","year":"2011","journal-title":"J Rehabil Res Dev"},{"key":"R8-20260710","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1109\/TBME.2017.2775100","article-title":"Sockets for limb prostheses: a review of existing technologies and open challenges","volume":"65","author":"Patern\u00f2","year":"2018","journal-title":"IEEE Trans Biomed Eng"},{"key":"R9-20260710","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.apmr.2008.07.015","article-title":"Determinants of skin problems of the stump in lower-limb amputees","volume":"90","author":"Meulenbelt","year":"2009","journal-title":"Arch Phys Med Rehabil"},{"key":"R10-20260710","doi-asserted-by":"crossref","first-page":"101060","DOI":"10.1016\/j.oto.2023.101060","article-title":"Pain management in limb loss","volume":"33","author":"Rai","year":"2023","journal-title":"Oper Tech Orthop"}],"container-title":["American Journal of Physical Medicine &amp; Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PHM.0000000000002989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:06:27Z","timestamp":1785765987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PHM.0000000000002989"}},"subtitle":["Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals With Lower Limb Amputation"],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/phm.0000000000002989","relation":{},"ISSN":["0894-9115","1537-7385"],"issn-type":[{"value":"0894-9115","type":"print"},{"value":"1537-7385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"2025-11-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}